Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.27), $0.01 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $21.58 million.

The company maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.